Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-28

Clinical Trial Update: Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial examining avadomide (CC-122) in combination with nivolumab in advanced melanoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avadomide (avadomide)
  • nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2022-09-28